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Abstract
Background: Calcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide whose biological
activity has potential therapeutic value for many vascular related diseases. CGRP is a 37 amino acid
neuropeptide that signals through a G protein-coupled receptor belonging to the secretin receptor family.
Previous studies on the calcitonin-like receptor (CLR), which requires co-expression of the receptor-
activity-modifying protein-1 (RAMP1) to function as a CGRP receptor, have shown an 18 amino acid N-
terminus sequence important for binding CGRP. Moreover, several investigations have recognized the C-
terminal amidated phenylalanine (F37) of CGRP as essential for docking to the mature receptor.
Therefore, we hypothesize that hydrophobic amino acids within the previously characterized 18 amino
acid CLR N-terminus domain are important binding contacts for the C-terminal phenylalaninamide of
CGRP.
Results:  Two leucine residues within this previously characterized CLR N-terminus domain, when
mutated to alanine and expressed on HEK293T cells stably transfected with RAMP1, demonstrated a
significantly decreased binding affinity for CGRP compared to wild type receptor. Additional decreases in
binding affinity for CGRP were not found when both leucine mutations were expressed in the same CLR
construct. Decreased binding characteristic of these leucine mutant receptors was observed for all CGRP
ligands tested that contained the necessary amidated phenylalanine at their C-terminus. However, there
was no difference in the potency of CGRP to increase cAMP production by these leucine mutant receptors
when compared to wild type CLR, consistent with the notion that the neuropeptide C-terminal F37 is
important for docking but not activation of the receptor. This observation was conserved when modified
CGRP ligands lacking the amidated F37 demonstrated similar potencies to generate cAMP at both wild
type and mutant CLRs. Furthermore, these modified CGRP ligands displayed a significant but similar loss
of binding for all leucine mutant and wild type CLR because the important receptor contact on the
neuropeptide was missing in all experimental situations.
Conclusion:  These results are consistent with previous structure-function investigations of the
neuropeptide and are the first to propose specific CLR binding contacts for the amidated F37 of CGRP
that are important for docking but not activation of the mature CGRP receptor.
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Background
Calcitonin gene-related peptide (CGRP) released from
sensory fibers originating in the trigeminal ganglia [1] or
the adventitial-medial border of arteries supplying the
heart [2] causes a potent, efficacious and long-lasting dila-
tion of cerebral and coronary vessels, respectively [3,4].
Vasodilatation of cerebral arteries by CGRP released from
trigeminal fibers is implicated in the pathogenesis of
migraine headaches [5]. Conversely, vasodilatation by
CGRP released in the peripheral vasculature might be of
considerable importance to patients suffering from hyper-
tension and/or heart disease [6,7]. For example, it has
been demonstrated that CGRP is essential for myocardial
protection, during reperfusion injury, either in ischemic
preconditioning or in heat stress-induced cardioprotec-
tion [8]. However, lack of small molecule non-peptide
CGRP receptor agonists or antagonists limit the essential
investigations that would assess the role of this neuropep-
tide in vascular related diseases.
Structure-function relationships of CGRP have been
extensively studied and are highlighted in a review by
Wimalawansa [9]. Briefly, this 37 amino acid neuropep-
tide can be divided into two distinct domains based upon
its binding and agonistic properties for the receptor. The
first N-terminal residues (1–7) have been shown to be
essential for receptor activation [10]. Specifically, loss of
the disulfide bridge connecting amino acids 2 and 7
negates all biological activity of the endogenous neu-
ropeptide [11]. However, deleting this portion of the
CGRP molecule does not appear to be critical for receptor
affinity [12]. Conversely, the N-terminal truncated pep-
tide, CGRP(8–37), is an effective CGRP receptor antago-
nist having a high affinity for the receptor but devoid of
any biological activity in itself [13]. More specifically, the
amidated C-terminal phenylalanine at position 37 of
CGRP has been shown to be necessary for receptor inter-
action since deletion of this peptide residue or loss of the
C-terminal amine results in a significant deficiency of
high affinity binding [14,15]. This affinity loss of des-F37-
CGRP for the native receptor when compared to the
endogenous neuropeptide is not due to disruption of the
ligand structure [16]. Instead, it is postulated that the C-
terminal phenylalaninamide of the ligand directly inter-
acts with the mature CGRP receptor in order for this high
affinity binding to occur. Moreover, conservative substitu-
tion of F37 for tyrosine, which adds only one hydroxyl
group to the phenol ring, again causes a significant loss of
binding affinity, supporting the idea that CGRP-F37 is
essential for high affinity interaction with the mature
receptor protein [17]. In addition, an α-helical configura-
tion incorporating residues 8–18 and β-sheet structures
related to amino acids 18–21 and 32–35 are also thought
to contribute to the high affinity receptor antagonist pro-
file of CGRP(8–37) [18,19]. However, there is no infor-
mation in the literature regarding specific interactions of
the receptor with these identified ligand domains, partic-
ularly the C-terminus phenylalaninamide of CGRP.
The receptor for CGRP is a heptahelical membrane pro-
tein that belongs to the group B family of G protein-cou-
pled receptors (GPCR). This GPCR family is distinct from
the well characterized group A rhodopsin family of
GPCRs in the fact that group B members have long extra-
cellular N-terminus domains and utilize moderately sized
peptides as their endogenous agonists [20]. The human
clone for this receptor has been identified and named the
calcitonin-like receptor (CLR) protein based on sequence
identity to the calcitonin receptor [21]. However, tran-
sient mammalian cell expression of the human CLR clone
could not be achieved until identification of a single trans-
membrane protein family called receptor-activity-modify-
ing proteins (RAMPs) that are essential for trafficking
mature CLR proteins to the cell membrane surface [22]. In
this study, heterodimerization of CLR-RAMP1 on the
membrane surface was shown to exhibit the pharmaco-
logical profile of an endogenously expressed CGRP recep-
tor. Conversely, interaction of CLR with RAMP2 or 3 on
the membrane surface demonstrated the pharmacological
receptor profile for a related peptide, adrenomedullin
(AM). Therefore, cell specific expression of distinctive
RAMPs with the CLR imparts selective pharmacological
receptor profiles for related peptide families.
Structure-function studies of group B GPCR families have
documented important interactions of the characteristi-
cally long N-terminal domain with their endogenous pep-
tide ligands [23,24]. Recent evidence has also addressed
the importance of the CLR N-terminal domain for dock-
ing with the endogenous neuropeptide. For example, a
purified CLR N-terminal domain overexpressed in E. coli
was able to specifically bind 125I-CGRP and could displace
this same radiolabeled peptide from a membrane prepa-
ration containing native CGRP receptors [25]. This obser-
vation supports previous structure-function analysis of
CGRP that describe two separate peptide domains essen-
tial for binding and agonism [11,15]. A model illustrating
this interaction of specific CGRP domains with the CLR-
RAMP1 heterodimer (i.e., mature CGRP receptor) is pre-
sented in figure 1.
Specific to the CLR, deletion of an 18 amino acid region
of the receptor N-terminal domain resulted in a signifi-
cant loss of 125I-CGRP binding when co-expressed in
mammalian cells with RAMP1 [26]. However, this CLR
deletion mutant was able to generate cAMP in a concen-
tration-dependent manner with increasing amounts of
CGRP. For our investigation, we considered whether the
essential C-terminus phenylalaninamide of CGRP was
contributing to high affinity neuropeptide binding byBMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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directly interacting with hydrophobic amino acids found
within this deleted CLR N-terminal domain. Therefore,
we used site-directed mutagenesis techniques to change
these hydrophobic CLR residues to alanine, then charac-
terized the binding and signaling properties of these tran-
siently expressed CLR mutants for the endogenous or
modified neuropeptides, comparing the results to wild
type receptor. In this study, we identify two specific leu-
cine residues within this N-terminal domain of the CLR
that significantly contribute to the high affinity binding of
CGRP without appreciably affecting receptor function.
Results
Competitive radioligand binding properties of CGRP and 
modified peptide ligands for wild type and mutant CLRs
Previous investigations have identified [125I-Tyr]CGRP(8–
37) as a selective high affinity radioligand for mature
CGRP receptors (i.e., CLR-RAMP1 heterodimers) endog-
enously expressed in rat brain and peripheral tissues [27].
Therefore, we used this same radiochemical to recognize
mature CGRP binding sites on HEK293T-RAMP1 cells
that had been transiently transfected with mutant and
wild type CLRs. Crude membrane preparations from these
transfected HEK293T-RAMP1 cells were used in satura-
tion binding experiments with increasing concentrations
of [125I-Tyr]CGRP(8–37) in the absence or presence of
1μM CGRP to define nonspecific binding. Preliminary
studies using non-transfected HEK293T-RAMP1 mem-
branes or membranes isolated from cells transiently trans-
fected with empty vector demonstrated no specific
binding with increasing concentrations of the radioligand
(data not shown). Conversely, HEK293T-RAMP1 mem-
branes transiently expressing the wild type CLR demon-
strated a saturable rise in specific binding as a result of
increasing [125I-Tyr]CGRP(8–37) concentrations (Fig 2).
The equilibrium dissociation constant of the radioligand
(Kd) and the maximal specific binding of [125I-
Tyr]CGRP(8–37) (Bmax) calculated from non-linear
regression analysis was 0.9 ± 0.2 nM and 285 ± 206 fmols/
mg of wild type membrane protein, respectively (n = 3).
This Kd value is similar to affinity constants calculated for
this radioligand when used in other investigations to
identify endogenous CGRP receptor binding sites [27].
Analogous saturation binding experiments were per-
formed for the L24A, L34A and L24A,L34A CLR double
mutant transiently expressed individually on HEK293T-
RAMP1 membranes with an approximate 10-fold
decrease in the [125I-Tyr]CGRP(8–37) Kd value calculated
for all receptor mutations (Table 1). These Kd values were
used to calculate equilibrium dissociation constants (Ki)
of competing CGRP receptor active ligands for transiently
expressed wild type and mutant CLR-RAMP1 heterodim-
ers using the method of Cheng and Prusoff [28].
Increasing concentrations of CGRP or the N-terminally
acetylated peptide fragment, AcCGRP(19–37) were used
to inhibit specific [125I-Tyr]CGRP(8–37) binding to mem-
branes prepared from HEK293T-RAMP1 cells transiently
transfected with wild type or mutant CLRs. Specific [125I-
Tyr]CGRP(8–37) binding was plotted versus increasing
concentrations of the endogenous or modified neuropep-
tide and a competition curve for each membrane prepara-
tion was generated using non-linear regression analysis
(Fig 3). When the IC50 of these curves were used to calcu-
late the Ki of CGRP for these transiently expressed mem-
brane proteins (Fig 3A), there was a significant 6 to 8-fold
decrease in affinity values for all mutant receptors (L24A
= 8.9 ± 3.1 nM, n = 3; L34A = 10.8 ± 2.2 nM, n = 4;
L24A,L34A = 9.3 ± 2.8 nM, n = 3) when compared to wild
type CLR (1.4 ± 0.3 nM, n  = 5). Likewise, the Ki of
AcCGRP(19–37) calculated from competition binding
experiments (Fig 3B) using transiently transfected wild
type CLR membranes (227 ± 86 nM, n = 3) was similar to
the equilibrium dissociation constant (933 ± 421 nM, n =
3) estimated from functional characterization of endog-
enous CGRP receptors expressed in the guinea pig atria
[29]. However, there was a significant 10 to 20-fold
decrease in the Ki values of AcCGRP(19–37) for the L24A
(3.0 ± 1.4μM, n = 3), L34A (4.6 ± 1.2μM, n = 3) and
L24A,L34A (2.0 ± 1.0μM, n = 5) double mutant CLR when
compared to wild type (Fig 3B). Since the amidated F37 is
Postulated interactions of specific CGRP domains with the  CLR-RAMP1 heterodimer Figure 1
Postulated interactions of specific CGRP domains 
with the CLR-RAMP1 heterodimer. Co-expression of 
the CLR with RAMP1 forms a mature CGRP receptor on the 
cell membrane surface. The characteristically long extracellu-
lar domains of the CLR-RAMP heterodimer create a high 
affinity binding pocket important for docking the C-terminal 
phenylalaninamide of CGRP. This interaction presents the 
CGRP N-terminus domain, essential for biological activity, to 
a "classical" agonist binding pocket formed in part by the 
transmembrane α-helices of the CLR-RAMP1 heterodimer.
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a common residue not only of the radioligand, but also
the two competitive peptides, similarities in binding affin-
ity loss lend support to our hypothesis that hydrophobic
N-terminus CLR amino acids are docking with the C-ter-
minal phenylalaninamide of the neuropeptide. Further-
more, there were no significant differences in affinity
values of the endogenous or modified competitive pep-
tides for single and double leucine CLR mutations, sug-
gesting that no synergistic binding relationship between
CGRP-F37 and these hydrophobic CLR residues is occur-
ring.
To specifically test this hypothesis we used modified pep-
tide ligands, which lacked the C-terminus phenylalanine
in additional competitive radioligand binding experi-
ments. There was a significant affinity loss of the C-termi-
nal amidated ligand, CGRP(1–36), for the wild type CLR
transiently expressed on HEK293T-RAMP1 membranes
when compared to the Ki of CGRP for the same receptor
(Table 1). However, there were no differences in CGRP(1–
36) affinity values for L24A, L34A and L24A,L34A recep-
tor mutants when compared to wild type CLR. To confirm
these observations we utilized another truncated CGRP
fragment, which was not amidated at the carboxyl termi-
nus. Similar to results using CGRP(1–36), there was a sig-
nificant loss of CGRP(1–19) affinity for the wild type CLR
when compared to the endogenous neuropeptide at the
same receptor (Table 1). Nevertheless, this CGRP(1–19)
affinity for the wild type receptor was analogous to values
calculated for all leucine CLR mutations. These results
emphasized the importance of the C-terminal F37 as an
important binding contact for the wild type CLR (12). In
addition, the lack of CGRP(1–36) or CGRP(1–19) affinity
value changes for mutant compared to wild type CLRs,
suggests that N-terminus leucines at positions 24 and 34
on the receptor might be interacting with F37 of the
endogenous neuropeptide.
Signaling properties of stimulated wild type and mutant 
CLRs using CGRP or modified receptor active peptide 
ligands
CGRP-F37 is hypothesized to be an important binding
contact for hydrophobic N-terminus residues on the CLR.
However, it is important to show if this ligand-receptor
contact is also central to activation mechanisms of the
mature membrane protein. Neuropeptide activation of
endogenously expressed CLR-RAMP1 heterodimers has
been shown to generate increases in cAMP [9]. Therefore,
we examined the characteristics of CGRP and other mod-
ified peptide agonists to generate cAMP in HEK293T-
Saturation binding characteristics of [125I-Tyr]CGRP(8–37) Figure 2
Saturation binding characteristics of [125I-
Tyr]CGRP(8–37). Increasing amounts of [125I-
Tyr]CGRP(8–37) were used on a crude HEK293T-RAMP1 
membrane preparation that had been transiently transfected 
with wild type CLR, in the absence and presence of 1μM 
CGRP to determine total and nonspecific binding, respec-
tively. Non-linear regression analysis was used to best fit a 
specific binding curve to each individual binding experiment. 
From this best fit curve an equilibrium dissociation constant 
(Kd) for the peptide radioligand and total number of specific 
binding sites (Bmax) were estimated. The Kd of [125I-
Tyr]CGRP(8–37) was calculated to be 0.9 ± 0.2 nM with a 
Bmax estimated at 285 ± 206 fmols/mg protein. The data pre-
sented represents the mean ± S.E. for n = 3 experiments per-
formed in duplicate.
Table 1: Comparisons of Kd and Ki values to previously published equilibrium dissociation constants for endogenous and modified 
CGRP ligands (in nM).
Peptide Ligand Wild Type Reported Wild Type L24A L34A L24A,L34A
[125I-Tyr]CGRP(8–37) 0.9 ± 0.2 0.2a 9.0 9.0 9.0
CGRP 1.4 ± 0.3 0.4H, 32L 
a 8.9 ± 3.1 10.8 ± 2.2 9.3 ± 2.8
AcCGRP(19–37) 227 ± 86 933b 3000 ± 1400 4600 ± 1200 2000 ± 1000
CGRP(1–36) > 10,000 n.d. > 10,000 > 10,000 > 10,000
CGRP(1–19) > 10,000 n.d. > 10,000 > 10,000 > 10,000
aVan Rossum et al., 1994; bRovero et al., 1992;
H and L represent high and low binding affinity values respectively calculated from a complex curve fitting model of the data points.BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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RAMP1 cells that had been transiently transfected with
wild type and leucine CLR mutations in order to test the
importance of these residues for receptor activation. Pre-
liminary studies using non-transfected HEK293T-RAMP1
cells or cells transiently transfected with empty vector
showed no production of cAMP after 30 min incubation
at 37°C with 10 nM CGRP (data not shown). Conversely,
increasing concentrations of CGRP generated rising
amounts of cAMP in HEK293T-RAMP1 cells transiently
expressing wild type or mutant CLRs (Fig 4A). The
potency of CGRP to generate cAMP in these cells trans-
fected with the wild type receptor (1.6 ± 0.1 nM, n = 3)
was not significantly different from HEK293T-RAMP1
cells expressing the L24A (1.5 ± 0.4 nM, n = 3), L34A (2.0
± 0.5 nM, n = 3) or double L24A,L34A (1.3 ± 0.2 nM, n =
3) CLR mutants. This suggests that modification of these
N-terminus CLR leucines to alanine, individually or in
tandem, does not affect the neuropeptide initiated signal-
ing of the membrane protein.
To support functional results observed for CGRP medi-
ated generation of cAMP through wild type and CLR
mutants, we used the truncated peptide, CGRP(1–36),
which lacked F37 but was still amidated at the C-termi-
nus. Increasing amounts of CGRP(1–36) was able to gen-
erate cAMP in HEK293T-RAMP1 cells transiently
expressing the wild type CLR in a concentration-depend-
ent manner (Fig 4B) The EC50 of CGRP(1–36) for the
expressed wild type CLR-RAMP1 heterodimer was calcu-
lated to be 4.3 ± 0.8μM (n = 3). Although the CGRP(1–
36) maximal response was similar, this EC50 was over
2,600-fold less than the value calculated for CGRP, indi-
cating the importance of the peptide C-terminus F37 for
receptor docking. Furthermore, increasing amounts of
CGRP(1–36) were also used on HEK293T-RAMP1 cells
transiently transfected with L24A, L34A or the L24A,L34A
CLR double mutant (Fig 4B). Potency values of CGRP(1–
36) to generated cAMP in these transfected cells were 3.4
± 0.7μM (L24A), 5.6 ± 0.8μM (L34A) and 4.2 ± 1.9μM
(L24A,L34A), respectively (n  = 3). These CGRP(1–36)
EC50 values for leucine CLR mutants were no different
when compared to the potency of this modified ligand for
increasing cAMP through the wild type receptor. Moreo-
ver, preincubation with 1μM of the CGRP receptor antag-
Competition binding characteristics of CGRP and AcCGRP(19–37) for wild type and mutant CLRs Figure 3
Competition binding characteristics of CGRP and AcCGRP(19–37) for wild type and mutant CLRs. Increasing 
amounts of (A) CGRP or (B) AcCGRP(19–37) were used to compete for specific [125I-Tyr]CGRP(8–37) binding sites on crude 
HEK293T-RAMP1 membrane preparations transiently transfected, individually with wild type (■), L24A (●), L34A (❍) or 
L24A,L34A (x) CLR mutations. Non-linear regression analysis was used to best fit a sigmoidal curve from the data points of 
each individual competition binding experiment. From this best fit curve the concentration of competing peptide need to dis-
place 50% of specific radioligand binding (IC50) was estimated and used to calculate the equilibrium dissociation constant (Ki) of 
unlabled peptide for each CLR. The calculated Ki values of the competing peptides for the L24A, L34A, or L24A,L34A CLR 
mutants were significantly different (P < .05) from the wild type receptor and are displayed in Table 1. The data presented rep-
resents the mean ± S.E. for n = 3–5 experiments performed in duplicate.BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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cAMP production of activated wild type and CLR mutants using endogenous or truncated CGRP ligands Figure 4
cAMP production of activated wild type and CLR mutants using endogenous or truncated CGRP ligands. 
Increasing amounts of (A) CGRP, (B) CGRP(1–36) or (C) CGRP(1–19) were used to stimulate confluent HEK293T-RAMP1 
cells that had been transiently transfected, individually with wild type (■), L24A (●), L34A (❍) or L24A,L34A (x) CLR muta-
tions. (B) Other groups of HEK-RAMP1 cells transiently transfected, individually with wild type (), L24A (), L34A (+) or 
L24A,L34A () CLR mutations were treated with 1μM of the CGRP receptor antagonist, CGRP(8–37), for 30 min prior to the 
addition of 10μM CGRP(1–36). After 30 min all cells were lysed and the amount of cAMP generated was quantified using a 
radioimmunoassay according to the manufactures protocol (Amersham). Non-linear regression analysis was used to best fit a 
sigmoidal curve from the data points of each individual experiment. From this best fit curve a concentration of peptide agonist 
that produced 50% of the maximal cAMP response (EC50) was estimated for each CLR. The calculated EC50 values of all pep-
tides to increase cAMP in HEK293T-RAMP1 cells transiently transfected with L24A, L34A or L24A,L34A CLR mutations were 
no different from values calculated for the wild type receptor and are displayed in table 2. The data presented represents the 
mean ± S.E. for n = 3 experiments performed in duplicate.BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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onist, CGRP(8–37), abolished the activity of 10μM
CGRP(1–36) to generate cAMP through the wild type and
leucine CLR mutants, indicating that this response was
receptor specific (Fig 4B).
To substantiate results using CGRP(1–36), we character-
ized another truncated CGRP receptor active peptide,
CGRP(1–19), which still lacked a C-terminal phenyla-
lanine. Increasing amounts of CGRP(1–19) were able to
generate increasing amounts of cAMP in HEK293T-
RAMP1 cells transiently expressing the wild type CLR in a
concentration-dependent manner (Fig 4C). The EC50 of
CGRP(1–19) for the expressed wild type CGRP receptor
was calculated to be 2.1 ± 0.6μM (n = 3). This EC50 value
was similar to the potency of CGRP(1–36), but was con-
siderably less than the calculated value of CGRP for the
wild type receptor. This potency loss substantiates previ-
ous findings that illustrate the importance of this C-termi-
nal CGRP-F37 for receptor docking. Furthermore, the
maximal response initiated by CGRP(1–19) was appreci-
ably less when compared to amounts of cAMP generated
by activating the wild type receptor using CGRP(1–36) or
the endogenous neuropeptide. This finding points to the
contribution of peptide residues linking the C-terminal
operative domains of CGRP for receptor agonism. Simi-
larly, increasing amounts of CGRP(1–19) were also used
on HEK293T-RAMP1 cells transiently transfected with
L24A, L34A or the L24A,L34A CLR double mutant (Fig
4C). Potency values of CGRP(1–19) to generated cAMP in
these transfected cells were 2.4 ± 0.2μM (L24A), 2.2 ±
0.6μM (L34A) and 1.6 ± 0.2μM (L24A,L34A), respectively
(n  = 3). EC50 values of CGRP(1–19) for these leucine
mutants are no different when compared to the potency
of this modified ligand to increase cAMP through the
expressed wild type receptor. The consistent loss of
potency for CGRP receptor active ligands lacking a C-ter-
minal phenylalanine compared to the endogenous pep-
tide support previous findings that highlight the
importance of CGRP-F37 for docking but not activating
the mature receptor and suggests that CRL residues L24
and L34 maybe required for this ligand-receptor interac-
tion.
Discussion
In this study we hypothesized that specific hydrophobic
amino acids from a previously characterized N-terminal
CLR deletion mutation [26] are important binding con-
tacts for the C-terminus phenylalaninamide of the endog-
enous neuropeptide. This premise is based upon earlier
structure-function investigations that divided CGRP into
two distinct domains based upon its binding and agonis-
tic properties for the endogenous receptor [9]. Initial
screening of all hydrophobic residues in this N-terminal
domain of the CLR revealed that two leucine residues
(L24 and L34), when mutated to alanine, demonstrated a
significant binding affinity loss of [125I-Tyr]CGRP(8–37),
CGRP or AcCGRP(19–37) for these specific CLR mutants
when compared to the wild type receptor (Table 1). Dif-
ferences in the magnitude of binding loss between CGRP
and AcCGRP(19–37) for the wild type versus mutant
CLRs can be attributed to the interaction of CGRP residues
8–18, which have been shown to also contribute towards
the high affinity binding value of the ligand-receptor
interaction [18,30]. Moreover, there were no additional
changes in the binding deficiency for [125I-Tyr]CGRP(8–
37), CGRP and AcCGRP(19–37) when both leucine
mutations were expressed in the same receptor protein,
indicating that there is a cooperative but not synergistic
relationship between these CLR residues for binding
CGRP-F37 ligands. Additionally, the C-terminal phenyla-
laninamide is a shared residue between [125I-
Tyr]CGRP(8–37), CGRP and AcCGRP(19–37). Therefore,
compared to wild type CLR, binding affinity losses of
these peptide ligands for the leucine CLR mutations sug-
gests that L24 and L34 are significant binding contacts
with CGRP-F37.
To support this hypothesis, we examined the binding
properties of truncated CGRP ligands lacking the C-termi-
nal phenylalanine for the wild type and leucine CLR
mutations. There was a significant binding affinity loss of
CGRP(1–36) or CGRP(1–19) when compared to the
endogenous neuropeptide for the wild type CLR. These
differences were not just due to modifications of func-
tional groups at the carboxyl end because CGRP(1–36)
was synthesized with an amidated C-terminus. Further-
more, this dissimilarity between CGRP(1–36) and CGRP
was not due to configuration variations because previous
biophysical measurements using circular dichroism spec-
troscopy and nuclear magnetic resonance have demon-
strated no significant differences in the secondary
structure of these peptides [16]. This deficiency in binding
affinity can be directly related to loss of the C-terminal
phenylalanine, as has been described by others [15].
However, this affinity loss was no different from wild type
receptor when CGRP(1–36) or CGRP(1–19) were used to
compete for specific L24A, L34A or L24A,L34A mutant
CLR binding sites on transiently transfected HEK293T-
RAMP1 cells. No changes in the binding parameters of
these truncated C-terminus CGRP ligands for mutant or
wild type CLRs indicates that similar contacts for peptide
docking are shared between these membrane proteins.
This is contrasted with binding affinity differences of
CGRP ligands having a C-terminal phenylalaninamide for
leucine CLR mutations versus wild type receptor. The only
variation between these two sets of experiments is the C-
terminus phenylalanine found on the endogenous neu-
ropeptide. This binding property difference of truncated
C-terminus peptide ligands versus CGRP for leucine
mutants and wild type receptor proteins, strongly advo-BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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cates CLR L24 and L34 as important binding contacts for
CGRP-F37. Moreover, this is the first description for iden-
tifiable binding contacts on the CLR that specifically inter-
acts with this essential neuropeptide phenylalaninamide.
We also assessed the functionality of these leucine CLR
mutants to increase the CGRP mediated production of
cAMP in an effort to understand the importance of these
receptor residues for agonist-dependent activation. When
compared to wild type receptor the potency of CGRP to
increase cAMP production was no different for all three
CLR leucine mutations (i.e., L24A, L34A and L24A,L34A;
see Table 2). This is contrary to the 6- to 8-fold loss of
CGRP binding affinity for these same CLR mutations. The
ability of CGRP to activate both mutant and wild type
receptors with similar potencies suggests there is some
plasticity in the agonist binding pocket that can overcome
variations in how the peptide docks with the receptor. As
figure 1 illustrates, changes in docking the C-terminal por-
tion of CGRP (i.e., F37) to these leucine CLR mutants,
may alter presentation of the N-terminus CGRP domain
to the agonist binding pocket of the mature receptor.
However, no changes in the potency of CGRP for the CLR
mutants versus wild type receptor indicates there is some
flexibility of the CLR agonist binding pocket that can over-
come modified docking arrangements of the neuropep-
tide. Moreover, this explanation for changes in CGRP
binding affinity with no differences in potency for mutant
versus wild type CLR supports the concept of two distinct
neuropeptide domains responsible for receptor binding
and agonism [31].
To validate this concept, we tested the ability of truncated
C-terminal CGRP ligands to increase generation of cAMP
in HEK293T-RAMP1 cells transiently expressing wild type
and leucine CLR mutations. If these modified CGRP lig-
ands still retain the essential agonist structures needed for
receptor activation, then a concentration-dependent
increase in the amount of cAMP generated should be
observed even though a necessary amino acid for ligand-
receptor docking is missing. For both CGRP(1–36) or
CGRP(1–19) there was a concentration-dependent
increase in the amount of cAMP produced from
HEK293T-RAMP1 cells transiently expressing the wild
type CLR (Table 2). However, the potency of these modi-
fied ligands was significantly less when compared to
CGRP mediated production of cAMP from the same wild
type receptor, which is directly related to loss of the phe-
nylalaninamide. These results are similar to investigations
where CGRP(1–36) was used for activating endogenous
CGRP receptors on acutely isolated pancreatic acinar cells,
to increase amylase release [32]. Conversely, there was no
significant potency differences of CGRP(1–36) or
CGRP(1–19) for increasing cAMP in HEK293T-RAMP1
cells transiently expressing any of the leucine CLR muta-
tions when compared to wild type receptor (Table 2). In
addition, this increased cAMP production was specific for
activating wild type or mutant CLRs because the response
was blocked to basal levels using an effective concentra-
tion of the receptor antagonist, CGRP(8–37). The consid-
erable binding affinity loss of truncated C-terminal CGRP
ligands for wild type or mutant CLRs, while still being
able to activate these same membrane proteins, validates
the concept put forth in this study and by others for two
distinct peptide ligand domains that manage docking and
agonism of the endogenous neuropeptide [31].
Compared to wild type receptor, 8- to 20-fold differences
in Ki values of these leucine CLR mutants for CGRP and
AcCGRP(19–37) are not as extensive when contrasted to
affinity changes of CGRP(1–36) and CGRP(1–19) for the
wild type receptor (Table 1). Absence of these leucine CLR
residues cannot explain the entire binding affinity loss of
CGRP(1–36) for the wild type receptor. Consequently, it
is reasonable to assume that interactions of CGRP-F37
with the mature CLR-RAMP1 heterodimer would necessi-
tate a more complex relationship in order to account for
the high affinity binding associated with the loss of this C-
terminal peptide residue. For example, the non-peptide
CGRP receptor antagonist, BIBN4096BS, has been shown
to exhibit high affinity for the endogenous CGRP receptor
expressed on SK-N-MC human neuroblastoma cells [33].
In addition, this small molecule CGRP receptor antago-
nist can selectively be displaced in competition binding
assays by CGRP and the receptor antagonist, CGRP(8–37)
[34]. Moreover, site-directed mutagenesis studies have
documented the importance of a specific extracellular
RAMP1 residue in determining BIBN4096BS antagonist
affinity for the mature CGRP receptor complex [35]. These
observations not only indicate the specificity of
BIBN4096BS for the mature CLR-RAMP1 heterodimer but
suggest that important high-affinity binding contacts on
Table 2: Potency (EC50) values of endogenous and modified CGRP ligands to generate cAMP in transiently transfected HEK293T-
RAMP1 cells (in nM).
Peptide Agonist Wild Type L24A L34A L24A,L34A
CGRP 1.6 ± 0.1 1.5 ± 0.4 2.0 ± 0.5 1.3 ± 0.2
CGRP(1–36) 4300 ± 800 3400 ± 700 5600 ± 800 4200 ± 1900
CGRP(1–19) 2100 ± 600 2400 ± 200 2200 ± 600 1600 ± 200BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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the mature receptor complex maybe common between
BIBN4096BS and CGRP. Therefore, it is plausible that the
complex high-affinity receptor binding contacts for
CGRP-F37 include not only leucine 24 and 34 on the N-
terminal domain of the CLR, but also extracellular resi-
dues of RAMP1.
To address this idea, a minimized molecular model of a
13 amino acid CLR N-terminal domain fragment interact-
ing with CGRP-F37 is put forward in figure 5. The α-heli-
cal structure of this receptor fragment puts L24 on the
opposite side of the helix from L34. We believe this mini-
mized secondary structure to be valid because a net nega-
tive charge is aligned with a specific face of this α-helix,
adjacent to L34. Interestingly, this same N-terminal recep-
tor domain has recently been demonstrated to mediate
structural interactions with RAMP1 [36]. Moreover, exam-
ination of the RAMP1 extracellular sequence reveals a
string of positively charged amino acids adjoining a non-
polar hydrophobic region of this accessory protein. We
propose that L34 and the adjacent negatively charged hel-
ical face of the CLR N-terminus domain interacts with this
extracellular region of RAMP1 to form a complex high
affinity binding pocket that includes L24 of the receptor.
Docking of CGRP-F37 would be accommodated by CLR
L24 and other residues formed by the L34 CLR-RAMP1
high affinity binding pocket. A deficiency of either CLR
L24 or L34 would cooperatively alter this high affinity
binding pocket leading to loss of binding affinity for any
CGRP receptor active ligand that contained a C-terminus
phenylalaninamide.
In summary, we have characterized specific leucine resi-
dues on the CLR membrane protein that participate in the
high affinity CGRP binding mediated by the C-terminal
phenylalaninamide of the neuropeptide. These CLR leu-
cine residues do not directly participate in CGRP medi-
ated receptor activation because they are not interacting
with residues identified with the "agonist" domain of the
peptide ligand. Alteration of either leucine CLR residue
accounts for a significant loss of CGRP affinity. In addi-
tion, this CGRP affinity loss is no different when both
leucines are modified in the same receptor protein, indi-
cating that there is not a synergistic relationship between
these CLR residues for CGRP binding. This paradigm for
distinct binding and activation domains on CGRP for the
mature receptor, as illustrated in figure 1, has also been
shown using biophysical measurements of the binding
mechanism for another group B GPCR [37]. Although
lacking the potential binding contributions of RAMP1,
which are currently being investigated, this study is the
first description of identifiable CLR residues important for
docking CGRP to the receptor and will be useful in future
studies that would build on our knowledge of this molec-
ular relationship.
Conclusion
This study is the first to describe specific amino acids on
the CLR N-terminus domain postulated to selectively
interact with the C-terminal phenylalaninamide of CGRP,
previously shown to impart the high affinity relationship
of the neuropeptide with the mature CGRP receptor. This
deduction is centered upon pharmacological properties of
site-directed CLR mutations that are analogous to previ-
ous structure-function properties of the endogenous neu-
ropeptide. Based on results from this study, a
fundamental model of CGRP interaction with these N-ter-
minus CLR leucine residues is brought forward. This
molecular model serves as a starting point for future stud-
ies that examine the relationship of the CLR in forming a
critical high affinity binding pocket with RAMP1 for
CGRP. Our increased knowledge of the mature CGRP
receptor binding pocket could lead to development of
selective non-peptide small molecule ligands that would
be useful in dissecting the important physiology of this
Working molecular model of CGRP phenylalaninamide inter- action with CLR residues L24 and L34 Figure 5
Working molecular model of CGRP phenylalanina-
mide interaction with CLR residues L24 and L34. 
Energy minimized models for CGRP amino acids 32–37 
(NH2-VGSKAF-CONH2) and CLR amino acids 23–35 (NH2-
ELEESPEDSIQLG-COOH) were performed as described in 
the "Methods". Hydrophobic interactions of CLR L24 and 
L34 with CGRP F37 and RAMP1 (not shown) cooperatively 
contributes to formation of the high affinity binding pocket 
essential for docking the C-terminal phenylalaninamide of the 
neuropeptide with the mature CGRP receptor heterodimer.BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
Page 10 of 12
(page number not for citation purposes)
abundant neuropeptide correlated with the pathological
mechanisms for many vascular related diseases.
Methods
Materials
Wild type human CLR clone (GenBank:NM 005795) was
a gift kindly provided by Steven M. Foord (GlaxoSmithK-
line Medicine Research Centre). Amidated CGRP(1–36)
was custom synthesized by The Cleveland Clinic Founda-
tion, Lerner Research Institute Core Peptide facility
(Cleveland, OH). CGRP, CGRP(8–37), CGRP(1–19) and
AcCGRP(19–37) was purchased from American Peptides
(Sunnyvale, CA). Tyr0-CGRP(8–37) was a gift from Phoe-
nix Pharmaceuticals (Belmont, CA). All peptides used for
this study were amidated at the peptide C-terminus except
CGRP(1–19). [125I-Tyr]CGRP(8–37) was synthesized by
Robert C. Speth at the University of Mississippi Peptide
Radioiodination Service Center (University, MS). Dul-
becco's minimum essential medium (DMEM) and fetal
bovine serum (FBS) was purchased from Atlanta Biologi-
cals (Atlanta, GA). HEK293T stably transfected with
RAMP1 was a gift kindly provided by Michel Bouvier
(University of Montreal, Quebec, Canada). cAMP Biotrak
enzyme-linked immunoassay was purchased from Amer-
sham Biosciences (Piscataway, NJ). Benzamidine, leupep-
tin, and phenylmethysulfonylfluoride was purchased
from Sigma-Alrich (St Louis, MO). Whatman GF/C filter
paper was purchased from Brandel (Gaithersburg, MD).
All other acids, bases and salts were of the highest purity
commercially available.
Site-directed mutagenesis
Site-directed mutagenesis was performed on a pcDNA3.1
human CLR construct utilizing QuickChange site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufactures instructions. Transformed plasmid DNA
from bacterial colonies that grew on selective media were
isolated (Qiagen, Valencia, CA) and sequenced by the
dideoxy method to verify the correct CLR mutation [38].
Mammalian cell culture
The parent and stably transfected HEK293 cell lines have
previously been shown not to express endogenous calci-
tonin receptor or CLR proteins [22,39,40]. CLR negative
HEK293T cells stably transfected with RAMP1 were prop-
agated in DMEM plus 10% FBS under standard cell cul-
ture conditions. Confluent HEK293T-RAMP1 cells were
washed in Hank's Balanced Salt Solution (HBSS),
trypsinized and seeded at the appropriate density in 35
mm 6-well plates or P-150 dishes to ensure 50–80% cell
confluence within 24 h. Transient transfection was per-
formed after 24 h with GeneJammer transfection reagent
according to the manufactures protocol (Stratagene, La
Jolla, CA) using a 3μL reagent per 2μg plasmid DNA ratio
for the transfection cocktail. Crude membrane prepara-
tions or cAMP signaling assays were performed on these
HEK293T-RAMP1 cells 60–72 h post-transfection.
Crude membrane preparation
A crude cell membrane preparation was prepared as previ-
ously described [41]. Briefly, HEK293T-RAMP1 mem-
branes were prepared by scraping and transferring cells to
a 50 mL conical tube using cold HBSS followed with two
washings by centrifugation at 1000 × g using cold HBSS.
The intact cell pellet was resuspended in 10 mL of 0.25 M
sucrose containing a protease inhibitor cocktail consisting
of 10μg/mL benzamidine, 10μg/mL leupeptin, and 20μg/
mL phenylmethysulfonylfluoride. The cells were dis-
rupted by freezing followed by Dounce homogenization
of the thawed suspension using 20 strokes from a loose
fitting (B) pestle. This mixture was then centrifuged at
1260 × g for 5 min at 4°C. Buffer A (20 mM HEPES, pH
7.5, 1.4 mM EGTA, 12.5 mM MgCl2, 10μg/mL benzami-
dine, 10μg/mL leupeptin, and 20μg/mL phenylmethysul-
fonylfluoride) was added to the supernatant and
centrifuged again at 30,000 × g for 15 min at 4°C. The
resultant pellet was kept, resuspended in buffer A then
centrifuged once more at 30,000 × g for 15 min at 4°C.
The final crude membrane pellet was resuspended in
buffer A containing 10% glycerol and stored in aliquots at
-70°C until used for radioligand binding. Protein concen-
trations were measured using the method of Bradford
[42].
Radioligand binding
The radioligand binding protocol used for this study was
performed as previously described [41]. Briefly, the den-
sity of expressed CLR-RAMP1 heterodimers on HEK293T
cells was determined by saturation binding experiments
using the selective CGRP receptor antagonist [125I-
Tyr]CGRP(8–37) as the radioligand. Crude HEK293T-
RAMP1 cell membranes were allowed to equilibrate in sil-
iconized polypropylene tubes at 37°C with increasing
concentrations of [125I-Tyr]CGRP(8–37) in a 0.25 mL
total volume of buffer A plus 0.1% BSA using 1μM CGRP
to determine non-specific binding. Binding was stopped
by filtering the membranes though Whatman GF/C glass
fiber filters, followed by 5 – 5 mL washes with cold buffer
B (20 mM HEPES, pH 7.5, 1.4 mM EGTA, 12.5 mM
MgCl2) to remove any unbound drug. Amounts of total
and non-specific radiolabel bound to cell membranes
were calculated from radioactive counts remaining on the
glass fiber filters. From the plotted saturation hyperbola,
CGRP receptor density (Bmax) and the equilibrium disso-
ciation constant (Kd) of [125I-Tyr]CGRP(8–37) for CLR-
RAMP1 heterodimer binding sites were calculated using
iterative non-linear regression analysis [43]. Competition
binding studies using increasing concentrations of unla-
beled CGRP receptor active ligands were performed in the
same buffer as the saturation binding experiments. Itera-BMC Pharmacology 2006, 6:9 http://www.biomedcentral.com/1471-2210/6/9
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tive non-linear regression analysis was again used to deter-
mine the concentration of unlabeled ligand that reduced
specific [125I-Tyr]CGRP(8–37) binding by 50% (IC50).
These IC50 values were used to calculate the equilibrium
dissociation constants (Ki) of competing CGRP ligands
for specific CLR-RAMP1 heterodimer binding sites
expressed on HEK293T cells using the method of Cheng
and Prusoff [28].
Quantitation of cAMP generation
60–72 h post-transfection, confluent HEK293T-RAMP1
cells were washed with HBSS then treated at 37°C in
serum-free DMEM containing 1 mM 1-methyl-3-iso-
butylxanthine (IBMX) to inhibit phosphodiesterase in the
presence or absence of 1μM CGRP(8–37). After 30 min,
increasing concentrations of CGRP receptor agonists were
added and the cells incubated for an additional 30 min at
37°C. At the end of this period, cells were lysed by 0.1M
HCl and collected for determining the amount of cAMP
generated using an enzyme-linked immunoassay accord-
ing to the manufactures protocol (Amersham Biosciences,
Piscataway, NJ). Briefly, 3H-cAMP added to cell lysates
was used to compete with the endogenously produced
cAMP for binding to a specific cAMP-binding protein. 3H-
cAMP levels were then counted by liquid scintillation and
related to endogenously generated cAMP by comparison
with known standards. The concentration of CGRP recep-
tor agonists that caused a half-maximal generation of
cAMP (EC50) was calculated using nonlinear regression
analysis (Graphpad, San Diego, CA).
Molecular modeling
The Biopolymer module in the Insight®II molecular mod-
eling package (Accelyrs, San Diego, CA) was used to build
models of CGRP residues 32–37 (NH2-VGSKAF-CONH2)
and CLR residues 23–35 (NH2-ELEESPEDSIQLG-
COOH). All charges were assigned for a pH value of 7.
After building the CGRP C-terminal hexapeptide as an
extended chain, backbone torsion angles of the peptide
sequence were modified to match those from the original
structure described by Breeze et al. [44]. The CLR peptide
was built as a helix then subjected to energy minimization
with the Discover module of Insight®II using the Amber
forcefield and a scalar dielectric constant of 78.54 (water
at 25°C) [45]. Energy minimization for the CLR peptide
was achieved in two stages. The first stage of 500 steps was
carried out using the steepest descents algorithm. The sec-
ond stage was performed using the conjugate gradient
algorithm with a convergence criterion of the derivative <
0.001, converging after 1390 iterations.
Statistical analysis
For each individual experiment, the fitted iterative nonlin-
ear regression curve that best represented the data was
determined using a partial f-test,  F  = [(SS1-SS2)/SS2]/
[(DF1-DF2)/DF2], where SS = sum of the squares and DF
= degrees of freedom (P < .05). From the best fit curve,
EC50 and Ki values were calculated and compared between
wild type and mutant CGRP receptors from concomi-
tantly transfected HEK293T-RAMP1 cells. Significance
between groups was tested using an unpaired two-tailed
Student's t test (P < .05). All values are reported as the
mean ± S.E. for n experiments, each performed in dupli-
cate.
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